Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations. AAV-based therapeutics have been the most successful in vivo gene therapies for patients with central nervous system disorders. Precision’s Deb Phippard identifies challenges to their development with assessing, minimizing and mitigating immunogenicity.